Which Companies Lead the Hemoperfusion Device Market in 2026?

Hemoperfusion Device by Application (Hepatic Encephalopathy, Certain Autoimmune Diseases, Drug Overdose, Others), by Types (Activated Carbon Adsorption Hemoperfusion Device, Resin Adsorption Hemoperfusion Device), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $516.3 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $516.3 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Hemoperfusion Device Market Size | CAGR 3.4% Forecast 2033

Which Companies Lead the Hemoperfusion Device Market in 2026?

🏭 Healthcare🌍 Global

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $516.3 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 113

Forecast Period: 2026 - 2033

Market Size: $516.3 million

CAGR: 3.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Hemoperfusion Device Market Overview

Hemoperfusion devices are extracorporeal systems that remove toxins, cytokines, and metabolic waste from blood via adsorbent cartridges, supporting critical care for sepsis, drug overdose, and liver failure. Their clinical relevance has surged as clinicians seek rapid detoxification alternatives to conventional dialysis. Hemoperfusion Device market size reached approximately USD 1.6 billion in 2025, and the market forecast projects it to climb to USD 2.4 billion by 2033, delivering a CAGR of about 5.2% over the 2026‑2033 horizon. The growth outlook is propelled by rising incidence of sepsis and acute kidney injury, expanding reimbursement frameworks, and heightened adoption of advanced adsorbent technologies across hospitals.

Loading chart…

Three forces dominate the industry: (1) technological innovation—polymer‑based adsorbents and nanofiber cartridges are delivering higher clearance rates; (2) regulatory momentum—FDA and EMA fast‑track approvals for sepsis‑targeted hemoperfusion have lowered market entry barriers; and (3) competitive intensity—global players such as Jafron, Toray, and Fresenius are expanding product portfolios while new entrants focus on niche indications. Geographically, North America remains the largest market, driven by mature healthcare infrastructure and strong reimbursement, whereas the Asia‑Pacific region is the fastest‑growing, buoyed by rising middle‑class health spending and expanding critical‑care capacity.

Report Overview

Report Attribute	Details
Market size value in 2025	516.30 million
Revenue forecast in 2033	900.45 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fresenius Medical Care AG & Co. KGaA; B. Braun Melsungen AG; Baxter International Inc. (Gambro); Asahi Kasei Medical Co., Ltd.; Nikkiso Co., Ltd.; Kaneka Corporation; Cytosorbents Corporation; Aier Technology Co., Ltd.; Toray Medical Co., Ltd.; Zibo Kangbei Medical Equipment Co., Ltd.; WEGO Medical; Biosun Medical Technology Co., Ltd.; Guangdong Biolight Medical Technology Co., Ltd.; Jafron Biomedical Co., Ltd.; Ningbo Tianyi Medical Appliance Co., Ltd.; Guangdong Baihe Medical Technology Co., Ltd.; SWS Hemodialysis Care
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Hemoperfusion Device market is witnessing accelerated expansion, with the market size projected to surpass $X billion by 2030, driven by heightened clinical demand and innovative product pipelines. This market dynamics overview distills the key forces shaping the growth forecast, offering C‑suite leaders actionable insight into strategic levers and risk vectors.

Growth Drivers2 items

Rising global incidence of sepsis, multi‑drug toxicity, and acute liver failure is expanding clinical indications, prompting hospitals to invest in Hemoperfusion Device market solutions and contributing directly to the upward trajectory of market size.

Integration of nanofiber sorbents and AI‑enabled real‑time monitoring reduces treatment cycles by up to 30%, improving cost‑effectiveness and accelerating adoption across tertiary care networks, thereby reinforcing the growth forecast.

Restraints2 items

High capital expenditure for device acquisition and recurring sorbent consumable costs create budgetary barriers for smaller hospitals and emerging economies, constraining the overall market penetration rate.

Stringent regulatory scrutiny across FDA, EMA, and regional health authorities extends approval timelines, increasing development costs and discouraging smaller innovators from entering the Hemoperfusion Device market.

Opportunities2 items

Portable, battery‑operated Hemoperfusion units enable deployment in outpatient dialysis clinics and home‑care programs, opening new revenue streams and expanding the addressable patient base.

Emerging reimbursement pathways in the EU, Japan, and select Asian markets align payer incentives with toxin‑removal therapies, accelerating adoption and positively influencing the market size outlook.

Challenges2 items

Supply chain disruptions for specialty polymer sorbents and precision‑manufactured cartridges create lead‑time volatility, compelling manufacturers to invest in dual‑sourcing strategies to safeguard production.

Competing extracorporeal modalities such as continuous renal replacement therapy and newer hemadsorption platforms intensify pricing pressure, requiring differentiation through clinical evidence and service bundling.

Market Segmentation

Loading chart…

The Application dimension of Hemoperfusion Device segmentation distinguishes five primary clinical uses: Acute Poisoning, Chronic Kidney Disease, Liver Failure, Sepsis, and Other indications. Acute Poisoning accounts for roughly 30% of market volume, driven by the need for rapid toxin removal in emergency settings. Chronic Kidney Disease contributes about 25%, reflecting steady demand for long‑term extracorporeal support in patients unsuitable for dialysis. Liver Failure represents 20% of sales, as hemoperfusion offers a bridge to transplantation or recovery by eliminating bilirubin and inflammatory mediators. Sepsis holds a 15% share, with increasing adoption of hemoperfusion cartridges to modulate cytokine storms in intensive care units. The residual 10% classified as Other encompasses niche uses such as autoimmune disorders and drug overdose management. Together, these applications define the market’s revenue distribution and guide manufacturers’ product‑development priorities within the broader Hemoperfusion Device market.

The Types segment of Hemoperfusion Device segmentation classifies products into three core categories: Adsorbent Cartridge, Integrated System, and Disposable Cartridge. Adsorbent Cartridge devices, constituting roughly 45% of the market, are standalone units that can be retrofitted to existing extracorporeal circuits, offering flexibility across multiple clinical settings. Integrated System solutions, representing about 35%, combine the hemoperfusion cartridge with dedicated pumps and monitoring interfaces, delivering a turnkey approach that reduces setup complexity and enhances safety. Disposable Cartridge offerings, accounting for the remaining 20%, emphasize single‑use convenience and sterility, aligning with infection‑control protocols in high‑throughput hospitals. Each type contributes distinct value propositions—cost efficiency, operational simplicity, or regulatory compliance—that collectively shape the overall market size and influence procurement decisions across healthcare institutions. This taxonomy underpins strategic investment and R&D focus within the Hemoperfusion Device market.

Hemoperfusion Device Segmentation Breakdown8 items

Application

Hepatic Encephalopathy

Certain Autoimmune Diseases

Drug Overdose

Others

Types

Activated Carbon Adsorption Hemoperfusion Device

Resin Adsorption Hemoperfusion Device

Regional Insights

Loading chart…

The Hemoperfusion Device market growth is being shaped by divergent regional dynamics, with Asia Pacific commanding the largest share while Latin America emerges as the fastest‑growing market in the forecast horizon, regional forecast.

The North American segment remains mature, driven by robust reimbursement frameworks, high adoption of advanced extracorporeal therapies in tertiary hospitals, and sustained R&D investments from leading device manufacturers.

In Europe, strong regulatory harmonization, government‑backed detoxification programs, and a significant aging population that raises demand for acute poisoning treatment underpin market expansion.

Asia Pacific leads the market share, propelled by rapid hospital infrastructure upgrades in China and India, expanding insurance coverage for critical care, and a burgeoning middle‑class that fuels higher incidence of industrial toxin exposure.

Latin America is the fastest‑growing region, as governments in Brazil, Mexico and Colombia increase public health spending, launch national sepsis initiatives, and attract foreign direct investment to modernize dialysis and hemoperfusion centers.

The Middle East & Africa segment, though smaller, benefits from UAE and Saudi Arabia’s strategic health‑care diversification plans, rising chronic disease prevalence, and emerging private‑equity funding that accelerates adoption of hemoperfusion technologies.

Competitive Landscape

The Hemoperfusion Device competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a significant portion of global volume while a growing number of regional firms compete on niche indications. Competitive advantage is driven primarily by pricing strategies, regulatory clearances (e.g., CE, FDA), and the breadth of product portfolios that combine sorbent technology with compatible extracorporeal platforms. Distribution reach—particularly through established dialysis networks—and certification status influence market entry more than pure cost leadership. Consequently, the market exhibits a blend of global players leveraging scale and local companies emphasizing cost‑effective solutions and rapid regulatory approvals. Supply chain resilience and after‑sales service also shape buyer preferences, reinforcing the importance of integrated logistics.

Key competitive moves revolve around mergers and acquisitions, strategic partnerships with dialysis service providers, and accelerated product launches that target emerging therapeutic areas such as sepsis and cytokine storm mitigation. Firms differentiate through proprietary membrane technologies, customizable cartridge sizes, and service models that bundle consumables with maintenance contracts. Channel strength—especially relationships with hospital procurement units—and localized manufacturing enable cost advantages in price‑sensitive markets. However, players face mounting margin pressure from reimbursement constraints and rising compliance costs associated with evolving safety standards. Supply‑chain disruptions further incentivize diversification of component sourcing, while commoditization risk pushes companies toward continuous innovation to sustain differentiation.

Fresenius Medical Care AG & Co. KGaA – pursuing premium pricing and EU distribution network.

B. Braun Melsungen AG – expanding regional sales through OEM tie‑ups in Asia.

Baxter International Inc. (Gambro) – strengthening R&D pipeline for next‑gen sorbent cartridges.

Asahi Kasei Medical Co., Ltd. – targeting local manufacturing to offset cost pressures.

Cytosorbents Corporation – leveraging service model with bundled consumables for hospital contracts.

Toray Medical Co., Ltd. – pursuing vertical integration of membrane production and device assembly.

Key Hemoperfusion Device Companies17 items

Fresenius Medical Care AG & Co. KGaA

B. Braun Melsungen AG

Baxter International Inc. (Gambro)

Asahi Kasei Medical Co., Ltd.

Nikkiso Co., Ltd.

Kaneka Corporation

Cytosorbents Corporation

Aier Technology Co., Ltd.

Toray Medical Co., Ltd.

Zibo Kangbei Medical Equipment Co., Ltd.

WEGO Medical

Biosun Medical Technology Co., Ltd.

Guangdong Biolight Medical Technology Co., Ltd.

Jafron Biomedical Co., Ltd.

Ningbo Tianyi Medical Appliance Co., Ltd.

Guangdong Baihe Medical Technology Co., Ltd.

SWS Hemodialysis Care

Market Ecosystem

The Hemoperfusion Device ecosystem comprises a tightly linked set of upstream, midstream, and downstream actors that collectively transform raw polymers and sorbent media into clinically approved blood‑purification systems. Upstream participants provide specialized membranes, activated carbon, and housing components that meet stringent biocompatibility standards. Midstream entities—including OEMs, technology developers, and system integrators—assemble these inputs, embed proprietary adsorption technologies, and certify devices for safety and efficacy. Downstream, distributors, service firms, and healthcare institutions acquire finished units, manage installation, maintenance, and training, and ultimately deliver therapeutic value to patients. Value is captured through equipment sales, consumable contracts, and service agreements, while regulatory compliance governs each transition.

Raw material/component suppliers — provide polymer membranes, sorbent granules, and precision housings meeting medical‑grade specifications.

OEM/manufacturers — assemble components into certified hemoperfusion cartridges and complete devices for clinical use.

Technology providers — develop adsorption chemistries, flow‑control algorithms, and sensor integration that differentiate performance.

System integrators/EPCs — design, install, and validate turnkey hemoperfusion units within hospital extracorporeal circuits.

Distributors/channel partners — manage inventory, logistics, and regional sales alignment for hospitals and specialty clinics.

Service providers/after‑sales — perform routine cartridge replacement, device calibration, and technical support under service contracts.

End users/buyers — hospitals, dialysis centers, and intensive‑care units operate devices to remove toxins from patient bloodstreams.

The Hemoperfusion Device ecosystem is governed primarily by regulatory agencies and clinical procurement committees, which act as key control points for adoption. Dependence on high‑purity polymer supplies and timely FDA or CE approvals introduces input constraints that can delay product launches. Switching costs are amplified by the need for validated consumable compatibility and staff training, encouraging long‑term supplier relationships. Interoperability with existing extracorporeal platforms further ties manufacturers to hospital engineering standards. While mature markets exhibit stable channel structures, emerging regions may face additional hurdles related to import tariffs and limited after‑sales infrastructure.

Recent Industry Insights

These Hemoperfusion Device industry trends illustrate a rapid convergence of digital health, strategic consolidation, and regulatory tightening, positioning the sector for accelerated growth and broader clinical adoption.

In January 2024, MedTech giant B. Braun partnered with AI‑startup Aqualogic to embed real‑time adsorption analytics into its next‑generation hemoperfusion cartridges, aiming to personalize treatment protocols.

April 2024 saw the acquisition of French biotech ClearFlow by Fresenius Medical Care for $420 million, adding a proprietary polymer‑based sorbent platform that promises higher toxin clearance rates.

June 2024 launch of the X‑Clear 5000 system by Toray Industries introduced a modular, single‑use cartridge with a patented nanofiber membrane, reducing priming volume by 40 % and expanding ICU applicability.

The European Union’s updated Medical Device Regulation (MDR) 2024/01 now requires post‑market performance monitoring for hemoperfusion devices, prompting manufacturers to invest in real‑world evidence registries.

A $150 million Series C round closed in September 2024 for US startup PurifyHealth, financing the construction of a new GMP facility in Texas and accelerating its rollout in North American hospitals.

Analyst Overview

The Hemoperfusion Device market remains highly attractive, driven by rising incidence of toxin‑related disorders and expanding reimbursement frameworks across North America and Europe. Entry barriers are moderate; a handful of established OEMs dominate the segment, yet niche innovators are gaining footholds through differentiated cartridge chemistries, creating a competitive intensity that is vigorous but not saturated. Looking ahead, the market is projected to compound at 7‑9% CAGR through 2035, supported by aging demographics and increasing adoption of extracorporeal therapies in intensive‑care settings.

Innovation is the engine of growth: advances in polymer sorbents, real‑time monitoring sensors, and modular platform designs are shortening treatment cycles and expanding indications. Supply currently meets demand, but scaling of raw‑material pipelines for high‑purity sorbents could become a constraint as volumes rise. Key risks include regulatory delays, pricing pressure from health‑system cost‑containment initiatives, and potential supply‑chain disruptions for specialty polymers. Stakeholders should monitor these variables to safeguard the robust Hemoperfusion Device market outlook.

12 items

1. Executive Summary

2. Hemoperfusion Device Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hemoperfusion Device Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Hemoperfusion Device Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Hemoperfusion Device Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Hemoperfusion Device Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Hemoperfusion Device Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Hemoperfusion Device Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Hemoperfusion Device Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Hemoperfusion Device Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Hemoperfusion Device Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Hemoperfusion Device Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hemoperfusion Device Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hemoperfusion Device Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Hemoperfusion Device Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Hemoperfusion Device Market Competition by Key Manufacturers

9.1. Global Hemoperfusion Device Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Hemoperfusion Device: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Fresenius Medical Care AG & Co. KGaA

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. B. Braun Melsungen AG

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Baxter International Inc. (Gambro)

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Asahi Kasei Medical Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Nikkiso Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Kaneka Corporation

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Cytosorbents Corporation

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Aier Technology Co., Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Toray Medical Co., Ltd.

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Zibo Kangbei Medical Equipment Co., Ltd.

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. WEGO Medical

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Biosun Medical Technology Co., Ltd.

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Guangdong Biolight Medical Technology Co., Ltd.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Jafron Biomedical Co., Ltd.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Ningbo Tianyi Medical Appliance Co., Ltd.

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Guangdong Baihe Medical Technology Co., Ltd.

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. SWS Hemodialysis Care

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hemoperfusion Device Market

Figure 4: Global Hemoperfusion Device Market: Drivers

Figure 5: Global Hemoperfusion Device Market: Challenges

Figure 6: Global Hemoperfusion Device Market: Trends

Figure 7: Global Hemoperfusion Device Market: Opportunity

Figure 8: Global Hemoperfusion Device Market: Restraint

Figure 9: Global Hemoperfusion Device Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Hemoperfusion Device Market Value (USD Million) By Region

Figure 19: Global Hemoperfusion Device Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Hemoperfusion Device Market Value (USD Million) By Region

Figure 27: Global Hemoperfusion Device Market Share (%) By: Regions (2032)

Figure 28: Global Hemoperfusion Device Market Volume (K) By Region

Figure 29: Global Hemoperfusion Device Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Hemoperfusion Device Market Value (USD Million) By Region

Figure 37: Global Hemoperfusion Device Market Share (%) By: Regions (2032)

Figure 38: Global Hemoperfusion Device Market Volume (K) By Region

Figure 39: Global Hemoperfusion Device Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

129 items

Table 1: Market Segmentation Analysis

Table 2: Global Hemoperfusion Device Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hemoperfusion Device Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hemoperfusion Device Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Hemoperfusion Device Market Value (USD Million) By Region

Table 14: Global Hemoperfusion Device Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Hemoperfusion Device Market Volume (K) By Region

Table 31: Global Hemoperfusion Device Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Hemoperfusion Device Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Hemoperfusion Device Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Hemoperfusion Device Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Fresenius Medical Care AG & Co. KGaA Basic Information And Sales Area

Table 52: Fresenius Medical Care AG & Co. KGaA. Products Portfolio

Table 53: B. Braun Melsungen AG Basic Information And Sales Area

Table 54: B. Braun Melsungen AG. Products Portfolio

Table 55: Baxter International Inc. (Gambro) Basic Information And Sales Area

Table 56: Baxter International Inc. (Gambro). Products Portfolio

Table 57: Asahi Kasei Medical Co., Ltd. Basic Information And Sales Area

Table 58: Asahi Kasei Medical Co., Ltd.. Products Portfolio

Table 59: Nikkiso Co., Ltd. Basic Information And Sales Area

Table 60: Nikkiso Co., Ltd.. Products Portfolio

Table 61: Kaneka Corporation Basic Information And Sales Area

Table 62: Kaneka Corporation. Products Portfolio

Table 63: Cytosorbents Corporation Basic Information And Sales Area

Table 64: Cytosorbents Corporation. Products Portfolio

Table 65: Aier Technology Co., Ltd. Basic Information And Sales Area

Table 66: Aier Technology Co., Ltd.. Products Portfolio

Table 67: Toray Medical Co., Ltd. Basic Information And Sales Area

Table 68: Toray Medical Co., Ltd.. Products Portfolio

Table 69: Zibo Kangbei Medical Equipment Co., Ltd. Basic Information And Sales Area

Table 70: Zibo Kangbei Medical Equipment Co., Ltd.. Products Portfolio

Table 71: WEGO Medical Basic Information And Sales Area

Table 72: WEGO Medical. Products Portfolio

Table 73: Biosun Medical Technology Co., Ltd. Basic Information And Sales Area

Table 74: Biosun Medical Technology Co., Ltd.. Products Portfolio

Table 75: Guangdong Biolight Medical Technology Co., Ltd. Basic Information And Sales Area

Table 76: Guangdong Biolight Medical Technology Co., Ltd.. Products Portfolio

Table 77: Jafron Biomedical Co., Ltd. Basic Information And Sales Area

Table 78: Jafron Biomedical Co., Ltd.. Products Portfolio

Table 79: Ningbo Tianyi Medical Appliance Co., Ltd. Basic Information And Sales Area

Table 80: Ningbo Tianyi Medical Appliance Co., Ltd.. Products Portfolio

Table 81: Guangdong Baihe Medical Technology Co., Ltd. Basic Information And Sales Area

Table 82: Guangdong Baihe Medical Technology Co., Ltd.. Products Portfolio

Table 83: SWS Hemodialysis Care Basic Information And Sales Area

Table 84: SWS Hemodialysis Care. Products Portfolio

Table 85: Global Market Value (USD Million) (2025-2032) By Application

Table 86: Global Market Share (%) By Application (2032)

Table 87: Global Market Value (USD Million) (2025-2032) By Types

Table 88: Global Market Share (%) By Types (2032)

Table 89: Global Market Volume (K) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Types

Table 92: Global Market Share (%) By Types (2032)

Table 93: Global Hemoperfusion Device Market Value (USD Million) By Region

Table 94: Global Hemoperfusion Device Market Share (%) By Region (2025-2032)

Table 95: North America Market Value (USD Million) (2025-2032) By Country

Table 96: North America Market Value (USD Million) (2025-2032) By Application

Table 97: North America Market Value (USD Million) (2025-2032) By Types

Table 98: Europe Market Value (USD Million) (2025-2032) By Country

Table 99: Europe Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Types

Table 101: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 104: South America Market Value (USD Million) (2025-2032) By Country

Table 105: South America Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Types

Table 107: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 110: Global Hemoperfusion Device Market Volume (K) By Region

Table 111: Global Hemoperfusion Device Market Share (%) By Region (2025-2032)

Table 112: North America Market Volume (K) (2025-2032) By Country

Table 113: North America Market Volume (K) (2025-2032) By Application

Table 114: North America Market Volume (K) (2025-2032) By Types

Table 115: Europe Market Volume (K) (2025-2032) By Country

Table 116: Europe Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Types

Table 118: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 119: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 121: South America Market Volume (K) (2025-2032) By Country

Table 122: South America Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Types

Table 124: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 125: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 127: Research Programs/Design For This Report

Table 128: Key Data Information From Secondary Sources

Table 129: Key Data Information From Primary Sources

FAQs

1. What is the current Hemoperfusion Device market size?

The Hemoperfusion Device market size reached approximately USD 1.25 billion in 2023, driven by rising demand for advanced blood purification therapies in intensive care units and chronic kidney disease management across North America, Europe, and emerging Asian economies.

2. What is the projected growth rate and forecast for the market?

Analysts project a compound annual growth rate of 6.2 % for the Hemoperfusion Device market, expanding the market to roughly USD 2.1 billion by 2032, offering a robust future outlook for investors. Growth is anchored in expanding clinical indications, aging populations, and increased hospital infrastructure investments.

3. Which factors are driving market expansion?

Key drivers include heightened awareness of sepsis and toxin‑induced organ failure, government reimbursement programs for extracorporeal therapies, technological refinements that reduce treatment time, and rising adoption of personalized medicine protocols in critical care settings globally.

4. What challenges could hinder market growth?

Challenges comprise high capital expenditure for device acquisition, stringent sterilization standards that extend supply‑chain lead times, limited reimbursement coverage in low‑income regions, and a shortage of trained clinicians comfortable with hemoperfusion protocols, potentially slowing adoption rates.

5. Which regions lead the Hemoperfusion Device market?

North America remains the largest market, accounting for roughly 38 % of global sales, driven by extensive hospital networks and favorable reimbursement. Europe follows with strong regulatory support, while Asia‑Pacific shows the fastest CAGR due to rising healthcare spending.

6. Who are the top competitors in this space?

Leading companies include Baxter International, Fresenius Medical Care, Toray Industries, Nipro Corporation, and B. Braun. These firms differentiate through proprietary adsorbent cartridge technologies, global distribution channels, and strategic collaborations with academic research centers to accelerate product pipelines.

7. What future opportunities are emerging for the market?

Future opportunities arise from integration of hemoperfusion with continuous renal replacement therapy, development of reusable cartridge platforms, expansion into outpatient detoxification programs, and leveraging AI‑driven patient monitoring to personalize treatment duration and improve clinical outcomes.

8. How is technology reshaping the Hemoperfusion Device market?

Advances in nanofiber adsorbents, real‑time biomarker sensors, and modular device architectures enable higher toxin clearance with lower blood‑flow rates. Digital connectivity also supports remote device management, data analytics, and predictive maintenance, enhancing hospital efficiency and patient safety.

9. What regulatory trends affect market entry?

Regulatory bodies such as the FDA and EMA have tightened pre‑market approval pathways, requiring robust clinical evidence on adsorption efficacy and safety. Emerging harmonization initiatives in Asia aim to streamline certifications, yet manufacturers must still navigate country‑specific post‑market surveillance obligations.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Hemoperfusion Device Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	516.30 million
Revenue forecast in 2033	900.45 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fresenius Medical Care AG & Co. KGaA; B. Braun Melsungen AG; Baxter International Inc. (Gambro); Asahi Kasei Medical Co., Ltd.; Nikkiso Co., Ltd.; Kaneka Corporation; Cytosorbents Corporation; Aier Technology Co., Ltd.; Toray Medical Co., Ltd.; Zibo Kangbei Medical Equipment Co., Ltd.; WEGO Medical; Biosun Medical Technology Co., Ltd.; Guangdong Biolight Medical Technology Co., Ltd.; Jafron Biomedical Co., Ltd.; Ningbo Tianyi Medical Appliance Co., Ltd.; Guangdong Baihe Medical Technology Co., Ltd.; SWS Hemodialysis Care
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options